December 4th 2023
Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.
November 29th 2023
Regulators have found that medications containing levetiracetam and clobazam have led to drug reaction with eosinophilia and systemic symptoms (DRESS), a rare and severe drug allergy.
November 27th 2023
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 25, 2024, for prademagene zamikeracel to treat patients with recessive dystrophic epidermolysis bullosa.
This is the second recall of Sandimmune related to the formulation of crystals in some bottles.
November 20th 2023
Contamination with Penicillium brevicompactum could lead to invasive fungal infections of the blood or pneumonia that can be life-threatening in immunocompromised patients.
Formulary Watch Drug Shortage Tracker — September 19, 2021
Pfizer Recalls All Lots of Smoking Cessation Drug Chantix
To date, Pfizer has not received reports of adverse events related to this recall, but is making the move as a precaution.
FDA Recalls Three Lots of Ruzurgi
The affected lots of this rare disease therapy have been contaminated with yeast, mold, and bacteria, which could lead to life-threatening infections.
Drug Shortages — September 12, 2021
FDA is Recalling One Lot of Firvanq
The lot contains kits with the incorrect solution for diluting vancomycin, which could lead to doses above or below recommended levels.
Drug Shortages Update — September 5, 2021
FDA’s New Warning Includes Xeljanz and other JAK Inhibitors
The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.
Teligent Recalls One Lot of Lidocaine
The product is considered “super potent” with a higher dose that could result in serious cardiac toxicities.
Hospital Pharmacists Concerned About Actemra Shortage
Pharmacists are referring patients elsewhere or are shifting patients who were using the IV form to the subcutaneous injection. The NIH has also recommended using Kevzara as an alternative where there are shortages of Actemra.
Drug Shortages Update—August 29, 2021
FDA Updates Black Box Warning for Linzess
The update indicates there is a serious risk of dehydration and is contraindicated in children.
Drug Shortage Tracker for August 22, 2021
Genentech Warns of Shortage of Actemra Due to Spike in COVID-19
The monoclonal antibody had been given an emergency use authorization to treat COVID-19, but the recent spike in cases is driving a shortage in supply.
Pfizer Recalls More Lots of its Smoking Cessation Drug Chantix
A total of 16 lots have been recalled.
Counterfeit Versions of Biktarvy and Descovy Found in Pharmacies
The bottles have a counterfeit foil seal or label and contain an incorrect number of tablets.
KVK Tech Recalls Two Lots of Atovaquone
The therapy for HIV-related pneumonia was exposed to cold weather during shipment.
Piqray’s Safety Label is Updated
Some fatal cases of ketoacidosis have occurred, and high-risk patients should be monitored when starting treatment.
FDA Safety Alert: Pepaxto is Associated with Increased Risk of Death
The agency has stopped enrollment in all ongoing trials.
Study: Blood Pressure Meds Work Equally, But One Has Fewer Side Effects
Angiotensin receptor blockers may be less likely to cause side effects than ACE inhibitors.
Merck Vaccine and Other FDA Updates
Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.
COVID-19 Vaccine Benefits Outweigh Low Risk of Developing Myocarditis, Study Finds
Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.
Apotex to Import Generic of Chantix from Canada
This is being done in coordination with the FDA to address the shortage created by the recall of Chantix. UPDATE: Pfizer has expanded its recall of Chantix from nine lots to 12 lots.
Study: Statins Reduce Death Rate in Patients with COVID-19
This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.
Several Lots of Human Growth Hormone Have Been Recalled
An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.
Jardiance Lowers Hospitalization Risk in Some Patients
Jardiance lowered risk of hospitalization from acute kidney injury but increased risk of hospitalized from diabetic ketoacidosis compared with a DPP4 inhibitor in one interim analysis.
Teva Recalls One Lot of Topotecan
While the risk of exposure is low, it presents a severe hazard.
FDA Approves Safety Updates to Synjardy Label
The label for the type 2 diabetes treatment has been updated to include the risk of ketoacidosis and damage to the kidney.
Bayer Introduces Updated Packaging for Stivarga
The anticancer therapy is now available in 21-count bottles to help accommodate dispensing.
Reducing Cardiac Toxicity During Cancer Treatment
Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.
ASCO Abstracts Focus on Adverse Events of Checkpoint Inhibitors
Immune-related AEs can occur one to two years after treatment, are more common in combination treatments, and can be difficult to manage.
2 Clarke Drive Cranbury, NJ 08512